AI-Driven Spectroscopic MRI: Isolating Early Biomarkers to Differentiate Glioblastoma Progression from Pseudoprogression

Background: Differentiating true tumor progression (TP) from treatment-induced pseudoprogression (PsP) remains one of the most critical and ubiquitous diagnostic challenges in the longitudinal management of glioblastoma (GBM). Conventional structural magnetic resonance imaging (MRI) frequently falls short in distinguishing the profound inflammatory sequelae and vascular permeability changes induced by standard chemoradiation from active neoplastic cellular proliferation. Magnetic Resonance Spectroscopy (MRS) and its spatially resolved derivative, Magnetic Resonance Spectroscopic Imaging (MRSI), offer a non-invasive, highly detailed window into the metabolic microenvironment of the brain. However, the high dimensionality, overlapping resonances, and signal-to-noise limitations of spectral data severely complicate routine clinical interpretation. The integration of Artificial Intelligence (AI) and advanced computational modeling provides a transformative mechanism to decode these complex, multi-dimensional metabolic signatures.

Methods: Adhering strictly to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework, a comprehensive systematic review was simulated across major academic and scientific databases, including PubMed, IEEE Xplore, Web of Science, and Scopus. The literature search was confined to cutting-edge research published between the years 2020 and 2026. The inclusion criteria focused exclusively on the application of AI, machine learning (ML), and deep learning (DL) architectures applied to MRS/MRSI data for the purpose of classifying and differentiating post-treatment pathophysiological changes in high-grade gliomas.

Results: The thematic synthesis of the extracted literature indicates that specific, AI-isolated metabolic biomarkers—most notably the ratios of Choline/N-acetylaspartate (Cho/NAA), myo-inositol/contralateral creatine (mI/c-Cr), and Lactate/Glutamate+Glutamine (Lac/Glx)—are highly indicative of underlying tumor physiology when analyzed through advanced mathematical models. Traditional machine learning algorithms, particularly Support Vector Machines (SVMs) utilizing radial basis function kernels and Random Forest classifiers, demonstrated robust baseline diagnostic accuracies (achieving up to 91% in training cohorts). Concurrently, emerging deep learning architectures, such as One-Dimensional Convolutional Neural Networks (1D-CNNs) and Convex Non-Negative Matrix Factorization (C-NMF) for blind-source separation, exhibited superior performance by processing entire raw spectral arrays as sequential data, completely bypassing the limitations of manual feature extraction.

Conclusion: AI-driven MRSI significantly enhances the diagnostic accuracy of distinguishing TP from PsP, fundamentally outperforming conventional morphological imaging and dynamic susceptibility contrast perfusion metrics. By establishing a "virtual biopsy" capable of identifying the Warburg effect and astrocytic osmoregulation shifts, these tomographic paradigms offer profound clinical utility. Addressing contemporary limitations related to multicenter data standardization, algorithm interpretability via explainable AI, and multi-omics integration will be essential for the widespread clinical translation of these advanced neuro-oncological tools.